ME Therapeutics Holdings Inc. (CSE: METX) has released a comprehensive programme update detailing meaningful progress across its in vivo CD19/CD22-targeted chimeric antigen receptor (CAR) pipeline and its therapeutic mRNA STING programme. The Vancouver-based biotechnology company has engineered two differentiated lead CAR constructs and successfully developed a novel liver-detargeted STING mRNA formulation showing promising in vitro results. On the corporate front, the company is actively working toward a NASDAQ listing, with its draft F-1 registration statement currently under review with U.S. securities regulators.

Key Points

  • ME Therapeutics Holdings Inc. (CSE: METX; FSE: Q9T) is a Vancouver-based biotechnology company targeting cancer and autoimmune disease
  • Two differentiated CD19/CD22-targeted in vivo CAR constructs are undergoing head-to-head preclinical comparison to select a final candidate
  • Candidate selection and entry into lipid nanoparticle formulation are expected in Q4 2026
  • Investors may be watching progress on the NASDAQ F-1 registration process and forthcoming preclinical CAR candidate selection data

Two CAR Architectures Enter Head-to-Head Preclinical Comparison

ME Therapeutics has advanced its in vivo CAR pipeline to produce two distinct lead constructs, both engineered to simultaneously target CD19 and CD22 — markers relevant to certain blood cancers and autoimmune diseases. The first uses a co-expression strategy pairing a CD19-targeting CAR with a dual-targeting CD22-directed construct. The second is a single tandem CAR fusing a CD19-targeting scFv directly to a CD22-targeting VHH antibody domain. The company states it is conducting head-to-head preclinical testing of expression and functional profiles, with results intended to determine the final development candidate.

Q4 2026 Target Set for LNP Formulation Phase Entry

Following candidate selection, ME Therapeutics plans to formulate its chosen in vivo CAR construct into T cell-targeting lipid nanoparticles (LNPs) for mRNA delivery. The company announced it expects to finalise candidate selection and advance into the LNP formulation phase during Q4 2026. The dual-targeting design is intended to address cancer cell escape mechanisms involving loss of CD19 expression, a known challenge in single-target approaches. The company did not disclose specific preclinical efficacy data or timelines beyond the Q4 2026 formulation milestone in the announcement.

Liver-Detargeted STING mRNA Formulation Shows Reduced Hepatocyte Expression In Vitro

In its therapeutic mRNA STING programme, ME Therapeutics reports the successful development of a liver-detargeted formulation designed to concentrate STING pathway activation within the tumour microenvironment while limiting liver exposure. The company states that in vitro testing demonstrated a significant decrease in STING protein expression in a human hepatocyte cell line, while expression in non-hepatocyte cells remained relatively unchanged. The next step disclosed is formulating this therapeutic mRNA into an LNP for in vivo testing. The company frames the approach as aimed at improving safety and specificity.

NASDAQ F-1 Registration Process Under Way with SEC Comment Round

ME Therapeutics disclosed it is actively pursuing a NASDAQ exchange listing as part of its corporate strategy. The company states it is working with U.S. counsel and is currently addressing the initial round of SEC comments on its draft F-1 registration statement. CEO Salim Dhanji indicated in the release that a NASDAQ listing is intended to broaden the company's investor base and support long-term growth. The immediate share price impact was not clear from available public information.